A paradigm shift in EPH receptor interaction: Biological relevance of EPHB6 interaction with EPHA2 and EPHB2 in breast carcinoma cell lines

Cancer Genomics and Proteomics

Volumn 8, Issue 4, 2011, Pages 185-193

  Fox, Brian P ^a   Kandpal, Raj P ^a  

^a Western University of Health Sciences   (United States)

Author keywords

Breast cancer; Co immunoprecipitation; EPH receptors; EPHA10; EPHA2; EPHB2; EPHB6; Protein protein interaction; Tumor suppressor

Indexed keywords

EPHRIN RECEPTOR; EPHRIN RECEPTOR A10; EPHRIN RECEPTOR A2; EPHRIN RECEPTOR B2; EPHRIN RECEPTOR B6; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER INVASION; CARCINOMA CELL; CONTROLLED STUDY; MAMMAL CELL; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION;

MAMMALIA;

EID: 79960452091     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Nakamoto M: Molecules in focus. Eph receptors and ephrins. Int J Cell Biochem Cell 32: 7-12, 2000.
2. Himanen JP, Chumley MJ, Lackmann M, Li C, Barton WA, Jeffrey PD, Vearing C, Geleick D, Feldheim DA, Boyd AW, Henkemeyer M and Nikolov DB: Repelling class discrimination: ephrin A5 binds to and activates EphB2 receptor signaling. Nature Neurosci 7: 501-509, 2004. (Pubitemid 38544589)
3. Pasquale EB: Eph receptor signalling casts a wide net on cell behavior. Nat Rev Mol Cell Biol 6: 462-475, 2005.
4. Kullander K and Klein R: Mechanisms and functions of Eph and ephrin signaling. Nature Cell Biol 3: 475-486, 2002. (Pubitemid 34733429)
5. Dodelet VC and Pasquale EB: Eph receptors and ephrin ligands: embryogenesis to tumorigenesis. Oncogene 19: 5614-9, 2000.
6. Surawska H, Ma PC and Salgia R: The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev 15: 419-433, 2004. (Pubitemid 39550453)
7. Campbell TNand Robbins SM: The Eph receptor/Ephrin system: an emerging player in the invasion game.Curr Issues Mol Biol 10: 61-66, 2008.
8. Zou JX, Wang B, Kalo MS, Zisch AH, Pasquale EB and Ruoslahti E: An Eph receptor regulates integrin activity through R-Ras. Proc Natl Acad Sci USA 96: 13813-13818, 1999.
9. Holmberg J, Clarke DL and Frisen J: Regulation of repulsion versus adhesion by different splice forms of an Eph receptor. Nature 408: 203-206, 2000.
10. Elowe S, Holland SJ, Kulkarni S and Pawson T: Down regulation of the Ras mitogen-activated protein kinase pathway by the EphB2 receptor tyrosine kinase is required for ephrin-induced neurite retraction. Mol Cell Biol 21: 7429-7441, 2001. (Pubitemid 32953493)
11. Miao H, Wei BR, Peehl DM, Li Q, Alexandrou T, Schelling JR, Rhim JS, Sedor JR, Burnett E and Wang B: Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat Cell Biol 3: 527-530, 2001. (Pubitemid 32422092)
12. Pratt RL and Kinch MS. Ligand binding up-regulates EphA2 messenger RNA through the mitogen-activated protein/ extracellular signal-regulated kinase pathway. Mol Cancer Res 1: 1070-1076, 2003. (Pubitemid 38044982)
13. Himanen J-P, Rajashankar KR, Lackmann M, Cowan CA, Henkemeyer M and Nikolov DB: Crystal structure of an Eph receptor-ephrin complex. Nature 414: 933-938, 2001. (Pubitemid 34024747)
14. Himanen JP and Nikolov DB: Eph signaling: a structural view. Trends Neurosci 26: 46-51, 2003.
15. Wimmer-Kleikamp SA, Janes, PW, Squire A, Bastiaens PIH and Lackmann M: Recruitment of Eph receptors into signaling clusters does not require ephrin contact. J Cell Biol 164: 661-666, 2004. (Pubitemid 38282950)
16. Fox BP and Kandpal RP: Invasiveness of breast carcinoma cells and transcript profile: Eph receptors and ephrin ligands as molecular markers of potential diagnostic and prognostic application. Biochem Biophys Res Comm 318: 882-892, 2004. (Pubitemid 38625856)
17. Fox BP and Kandpal RP. EphB6 receptor significantly alters invasiveness and other phenotypic characteristics of human breast carcinoma cells. Oncogene 28: 1706-13, 2009.
18. Tang XX, Zhao H, Robinson ME, Cnaan A, London W, Cohn SL, Cheung NK, Brodeur GM, Evans AE and Ikegaki N: Prognostic significance of EPHB6, EFNB2, and EFNB3 expressions in neuroblastoma. Med Pediatr Oncol 35: 656-658, 2000.
19. Tang XX, Evans AE, Zhao H, Cnaan A, Brodeur GM and Ikegaki N: Association among EPHB2, TRKA, and MYCN expression in low-stage neuroblastomas. Med Pediatr Oncol 36: 80-82, 2001.
20. Tang XX, Robinson ME, Riceberg JS, Kim DY, Kung B, Titus TB, Hayashi S, Flake AW, Carpentieri D and Ikegaki N: Favorable neuroblastoma genes and molecular therapeutics of neuroblastoma. Clin Caner Res 10: 5837-5844, 2004. (Pubitemid 39180963)
21. Hafner C, Bataille F, Meyer S, Becker B, Roesch A, Landthaler M and Vogt T: Loss of EphB6 expression in metastatic melanoma. Int J Oncol 23: 1553-1559, 2003.
22. Müller-Tidow C, Diederichs S, Bulk E, Pohle T, Steffen B, Schwäble J, Plewka S, Thomas M, Metzger R, Schneider PM, Brandts CH, Berdel WE, and Serve H: Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer. Cancer Res 65: 1778-1782, 2005. (Pubitemid 40478604)
23. Freywald A, Scharfe and Roifman CM: The kinase-null EphB6 receptor undergoes transphosphorylationin a complex with EphB1. J Biol Chem 277: 3823-3828, 2002.
24. Matsuoka H, Obama H, Kelly ML, Matsui T and Nakamoto M: Biphasic function of the kinase-defective EphB6 receptor in cell adhesion and migration. J Biol Chem 280: 29355-63, 2005. (Pubitemid 41161391)
25. Munthe E, Rian E, Holien T, Rasmussen A-M, Levy FO and Aasheim H-C: Ephrin-B2 is a candidate ligand for the Eph receptor, EphB6. FEBS Lett 466: 169-174, 2000. (Pubitemid 30050706)
26. Fox BP and Kandpal, RP: Yeast two-hybrid assay reveals several interactors of Ephb6 receptor. Open Proteomics J 1: 79-86, 2008.
27. Himanen JP and Nikolov DB: Molecules in focus. Eph receptors and ephrins. Int J Biochem Cell Biol 35: 130-134, 2003.
28. Freywald A, Sharfe N, Rashotte C, Grunberger T and Roifman CM: The EphB6 receptor inhibits JNK activation in T lymphocytes and modulates T-cell receptor-mediated responses. J Biol Chem 278: 10150-10156, 2003. (Pubitemid 36800273)
29. Luo H, Wan X, Wu Y and Wu J: Cross-linking of EphB6 resulting in signal transduction and apoptosis in Jurkat cells. J Immunol 167: 1362-1370, 2001. (Pubitemid 32703133)
30. Yu J, Bulk E, Ji P, Hascher A, Tang M, Metzger R, Marra A, Serve H, Berdel WE, Wiewroth R, Koschmieder S and Müller-Tidow C: The EPHB6 receptor tyrosine kinase is a metastasis suppressor that is frequently silenced by promoter DNA hypermethylation in non-small cell lung carcinoma. Clin Cancer Res 16: 2275-2283, 2010.
31. Parri M, Taddei ML, Bianchini F, Calorini L and Chiarugi P: EphA2 re-expression prompts invasion of melanoma cells shifting from mesenchymal to amoeboid-like motility style. Cancer Res 69: 2072-2081, 2009.
32. Zelinski DP, Zantek ND, Stewart JC, Irizarry AR and Kinch MS: EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 61: 2301-2306, 2001. (Pubitemid 32692063)
33. Fang WB, Brantley-Sieders DM, Parker MA, Reith AD and Chen J: A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis. Oncogene 24: 7859-68, 2005. (Pubitemid 41715192)
34. Lackmann M and Boyd AW: Eph, a protein family coming of age: more confusion, insight, or complexity? Sci Signal 1: re2, 2008.
35. Salaita K, Nair PM, Petit RS, Neve RM, Das D, Gray JW and Groves JT: Restriction of receptor movement alters cellular response: physical force sennsing by EphA2. Science 327: 1380-1385, 2010.
36. Zantek ND, Azimi M, Fedor-Chaiken M, Wang B, Brackenbury R and Kinsch MS: E-Cadherin regulates the function of the EphA2 receptor tyrosine kinase. Cell Growth Differ 10: 629-638, 1999. (Pubitemid 29455727)
37. Dobrzanski P, Hunter K, Jones-Bolin S, Chang H, Robinson C, Pritchard S, Zhao H and Ruggeri B: Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Cancer Res 64: 910-919, 2004. (Pubitemid 38176892)
38. Bowden TA, Aricescu AR, Nettleship JE, Siebold C, Rahman-Huq N, Owens RJ, Stuart DI and Jones EY: Structural plasticity of eph receptor A4 facilitates cross-class ephrin signaling. Structure 17: 1386-1397, 2009.
39. Alazzouzi H, Davalos V, Kokko A, Domingo E, Woerner SM, Wilson AJ, Konrad L, Laiho P, Espín E, Armengol M, Imai K, Yamamoto H, Mariadason JM, Gebert JF, Aaltonen LA, Schwartz Jr S, and Arango D: Mechanisms of inactivation of the receptor tyrosine kinase EPHB2 in colorectal tumors. Cancer Res 65: 10170-3, 2005. (Pubitemid 41743705)
40. Liu W, Jung YD, Ahmad SD, McCarty MF, Stoeltzing O, Reinmuth N, Fan F and Ellis LM: Effects of overexpression of ephrin-B2 on tumor growth in human colorectal cancer. Br J Cancer 90: 1620-6, 2004. (Pubitemid 38648248)
41. Qin H, Noberini R, Huan X, Shi J and Pasquale EB and Song J: Structural characterization of the EphA4-EphrinB2 complex reveals new features enabling Eph-ephrin binding promiscuity. J BiolChem 285: 644-654, 2010.
42. Singla N, Goldgur Y, Xu K, Paavilainen S, Nikolov DB and Himanen JP. Cyrstal structure of the ligand-binding domain of the promiscuous EphA4 receptor reveals two distinct conformations. BiochemBiophys Res Commun 399: 555-559, 2010.
43. Noberini R, Koolpe M, Peddibhotla S, Dahl R, Su Y, Cosford NDP, Roth GP and Pasquale EB: Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors. J Biol Chem 283: 29461-29472, 2008.
44. Schrencik JE, Brooun A, Recht MI, Kraus ML, Koolpe M, Kolatkar AR, Richard H. Bruce RH, Martiny-Baron G, Widmer H, Pasquale EB and Kuhn P: Structure and thermodynamic characterization of the EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor selectivity. Structure 14: 321-330, 2006. (Pubitemid 43202021)
45. Mitra S, Duggineni S, Koolpe M, Zhu X, Huang Z and Pasquale EB. Structure-activity relationship analysis of peptides targeting the EphA2 receptor. Biochemistry 49: 6687-6695, 2010.